Oncology Center Excellence LumaBridge has been acquired by Avance Clinical to strengthen its global oncology offering and establish a dedicated Oncology Center of Excellence. The combination brings experienced oncology leadership and robust US operations, with a proven track record in executing complex cancer trials across early and late phases. This integration creates opportunities to cross sell oncology CRO capabilities to Avance's biotech and pharma clients and to pursue larger multiregional studies.

Leadership Momentum Todd Lehman was appointed CEO in 2024, bringing a strong business development focus and a history of delivering process improvements. The leadership team includes Amanda Ferrier as COO, strengthening operational management. This combination supports faster deal closure and scalable delivery for oncology trials.

US Operations Advantage LumaBridge maintains robust US operational capabilities which complement Avance's global footprint. Positioned as the US hub for oncology trials, the company can enable faster site activation, regulatory readiness, and seamless execution for North American studies.

Specialized Oncology Focus The company specializes in oncology with experience across early and late phase cancer studies, offering innovative trial design and execution. This enables a differentiated value proposition to emerging biopharma clients seeking specialized oncology CRO support.

Strategic Network Access As part of Avance, LumaBridge gains access to a broader client network of biotech and pharma companies, creating upsell opportunities to expand oncology CRO services across the portfolio including trial management and data related services.